UNIVERSITY OF PORTLAND SCHOOL OF NURSING

Increasing Prevention of HPV-related Cervical Cancers

Abby Dolor, Henry Liang, Ali Jabusch, Jaelyn Tanga, & Jem Viernes

Problem

- 90% of cervical cancers are caused by the Human ulletPappilomavirus (HPV)
- 2012-2016: Median age among women for HPV-rela cervical cancer was 49 years old (CDC, 2019c)

Findings

HPV vaccines

- FDA-approved HPV vaccine recommended to age
- Adviosry Committee on Immunization Practices (A does not recommend vaccine for adults older than 2 (CDC, 2019a)

Cervical Cytology (Pap Smears)

- Looks at precancerous and cancerous cells related t cervical cancer
- Recommend every 3 years (Kaiser Permanente, 20)


High-risk HPV (hrHPV)

- Provides higher sensitivity in detecting indicators of HPV-related cervical cancer
- Recommend every 5 years with the potential to exte interval time between screenings to reduce unneces treatment (Kaiser Permanente, 2019a; Vink et al., 2019)

Co-testing

- Pap smear and hrHPV testing
- Recommend every 5 years (Kaiser Permanente, 20)

	Recommenda
ated	Shift to High-rsk HPV t screening tool for middle
45 ACIP) 26	Cervical Cervical
19a) of	Advocate for a chang incidence and prevale cancer
tend ssary 2015)	国際変更になっていた。
19a)	Acknowledger Kala Mayer, RN, PhD & Barb E



Discussion		
Pros	Cons	
ore effective and nger-lasting protection	• Assumptions that it detects all cervical	
igh negative predictive lue (Olgilvie et al., 017) otential for self- llection (Olgilvie et	cancers (Flanagan, 2018) • Roche Cobas HPV test is the only FDA approved hrHPV testing (Kaiser	
, 2017)	Permanente, 2019a)	
an lead to long-term vings (Felix et al., 016)	 Study showed co- testing was costlier than hrHPV testing alone (Jin et al., 2016) 	

Implementation

Advocacy and education of the effectiveness that hrHPV testing provides for this specific population



